With an intensive cooperation with top ophthalmic centers and surgeons, Vesber Biotechnology Co., already developed its distinctive competence as a a successful high-tech ophthalmic medical company.
In order to find the vitreous substitute which can support the retina for a long time and keep the complete structure and residual function. The inventor has proposed the idea of FCVB.
The establishment of company
The First Inspection of FCVB
First Clinical Trial of FCVB
We have conducted the first trial in the world in Jun,2009, and carried out the multi-center clinical trials in China continually. Finally we completed the selection of multi-center clinical trials in Jul, 2012.
Obtain the CE certificate
We have conducted the official European application in Greece, UK, Turkey and Belgium.
Get the CFDA registration certificate
The first FCVB milestone in Russia.
The first FCVB surgery in Pakistan.
Moving to our new factory – Vesber ‘s new branch at Guangdong Medical Center, Nansha District, in Guangzhou